NSE ONESOURCE · BSE 544292 · Biotechnology & Drugs · NIFTY 500

Onesource Specialty Pharma Share Price

Market open · NSE price as of Fri 25 Sep, 9:59 AM IST
₹1,600.00 ▲ +₹10.65 · 0.67%
Day range · 25 Sep
₹1,567.30Low₹1,633.55High
52-week range
₹1,075.00Low · 30 Jan 2026₹1,924.00High · 3 Nov 2025

Onesource Specialty Pharma Overview

Where the price stands, how it has moved and how it sits against its averages.

Onesource Specialty Pharma shares last traded at ₹1,600.00 on the NSE, up 0.67% on the day. That is 16.8% below the 52-week high of ₹1,924.00 and 48.8% above the 52-week low of ₹1,075.00. Its market value is ₹18,323 Cr.

Price returns

1 Day▲ +0.67%
1 Week0.00%
This month▲ +4.97%
3 Months▲ +2.48%
6 Months▲ +19.53%
This year▼ −11.93%
1 Year▼ −9.03%

Against the market: 1 Month ▲ +9.87% · 3 Months ▲ +7.38% · 6 Months ▲ +22.28% · This year ▲ +2.00% · 1 Year ▲ +1.03%

Shading grows with the size of the move. We ask our data provider for a newer price every 15 minutes while the market is open (9:15 AM–3:30 PM IST). Its quotes are not real-time — the time at the top shows how current the price is.

Moving averages — price is above 5 of 6

  1. 100-day average₹1,650.75 ▼ price 3.1% below
  2. Today's price₹1,600.00
  3. 5-day average₹1,596.20 ▲ price 0.2% above
  4. 10-day average₹1,594.43 ▲ price 0.3% above
  5. 50-day average₹1,584.05 ▲ price 1.0% above
  6. 300-day average₹1,583.95 ▲ price 1.0% above
  7. 20-day average₹1,569.26 ▲ price 2.0% above

Each average is the mean closing price over that many trading days; averages above the current price sit higher on the ladder.

Onesource Specialty Pharma Financial Results

Revenue and net profit in ₹ crore, with the full statements underneath.

Revenue₹ crore
1,445
1,422
Net profit₹ crore · losses below zero
−800
−18
−74

Year by year

Fiscal yearRevenueGrowthNet profitNet marginEPSDividend
FY 2026 ₹1,422 Cr ▼ −1.6% −₹74 Cr −5.2% −₹6.44 —
FY 2025 ₹1,445 Cr ▲ +740.4% −₹18 Cr −1.2% −₹1.57 —
FY 2024 ₹172 Cr ▲ +344.1% −₹391 Cr −227.5% −₹31.96 ₹0.00
FY 2023 ₹39 Cr — −₹800 Cr −2,066.2% −₹36.32 ₹0.00

Balance sheet — FY26

Owes (liabilities)Shareholders' equity
29%
71%
  • Total assets₹8,210 Cr
  • Total liabilities₹2,379 Cr
  • Shareholders' equity₹5,831 Cr
  • Total debt₹1,504 Cr
  • Cash & investments₹48 Cr
  • Current ratio0.99×
  • Operating margin (TTM)2.90%
  • Net margin (TTM)−3.15%

Cash flow — FY26

Operating activities
▲ ₹9 Cr
Investing activities
▼ −₹495 Cr
Financing activities
▲ ₹359 Cr
Free cash flow
▼ −₹561 Cr
Net change in cash
▼ −₹127 Cr

Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.

Full financial statements, FY23–FY26
₹ croreFY23FY24FY25FY26
Total revenue38.71171.921,444.851,421.59
Cost of revenue40.5090.64471.16480.18
Gross profit−1.7881.28973.70941.41
Operating expenses400.34446.011,361.181,437.63
Operating income−361.63−274.0983.68−16.04
Depreciation65.6876.29273.88279.09
Profit before tax−415.65−365.70−67.07−91.96
Tax0.000.00−49.79−18.16
Net profit−799.83−391.17−17.97−73.80
EPS (₹)−36.32−31.96−1.57−6.44
Dividend per share (₹)0.000.00——

Onesource Specialty Pharma vs Peers

Side by side with other biotechnology & drugs companies. The small bars compare each column.

CompanyPriceChangeMarket capP/EP/BROE (5 yr)Net marginDiv. yield
Onesource Specialty Pharma This stock ₹1,600.00 ▲ +0.67% ₹18,323 Cr −376.94 3.14 — −3.15% 0.00%
Sun Pharmaceutical Industries ₹1,853.50 ▲ +0.03% ₹4,44,706 Cr 38.40 5.55 14.22% 19.12% 0.83%
Divi's Laboratories ₹9,610.00 ▼ −0.03% ₹2,55,115 Cr 73.32 11.48 16.87% 24.32% 0.41%
Torrent Pharmaceuticals ₹4,985.00 ▲ +1.01% ₹1,89,607 Cr 72.73 19.22 23.00% 15.29% 0.80%
Cipla ₹1,397.20 ▼ −0.48% ₹1,12,874 Cr 27.57 3.33 14.47% 13.74% 0.92%
Zydus Lifesciences ₹1,202.00 ▲ +1.86% ₹1,19,900 Cr 21.19 4.24 17.90% 18.51% 0.09%

Peer prices and ratios as last reported by the data provider. Company names link to their own pages.

Shareholding Pattern

Who owns Onesource Specialty Pharma shares, quarter by quarter (latest on top).

PromoterFIIMFOther
Jun '26
30.5%
19.2%
13.0%
37.4%
Mar '26
Dec '25
Sep '25
HolderSep '25Dec '25Mar '26Jun '26Change
Promoter29.77%29.93%30.48%30.48% 0.00 pts
FII19.39%19.24%17.50%19.19% ▲ +1.69 pts
MF8.99%9.02%10.13%12.98% ▲ +2.85 pts
Other41.85%41.81%41.89%37.35% ▼ −4.54 pts

Onesource Specialty Pharma Key Metrics

Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.

Onesource Specialty PharmaBenchmarkRule-of-thumb bands

Valuation The price against earnings, book value and sales

P/E (TTM)Price ÷ yearly earnings per share
−376.94
Loss-making over 12 months — P/E not meaningful
P/BPrice ÷ book value per share
3.14
P/SMarket cap ÷ last 12 months' revenue
11.87
P/CFPrice ÷ cash flow per share
78.01

Profitability Of every ₹100 of sales, how much is kept?

Gross marginKept after the cost of goods
67.83%
Operating marginKept after running costs
2.90%
Pre-tax marginKept before tax
−4.36%
Net marginKept as profit
−3.15%

Returns & efficiency How well does it use its money?

Return on equityProfit on shareholders' money
−1.26%
Return on assetsProfit on everything it owns
−0.94%
Return on investmentProfit on long-term capital
−1.12%
Return on capital employedProfit before interest and tax on equity + debt
−0.35%

Growth Is the business getting bigger?

Revenue — last 12 months
+4.3%
▲ growing
Revenue — 3 yr, a year
+232.4%
▲ growing (off the scale)
EPS — last 12 months
−173.9%
▼ shrinking (off the scale)

Financial strength Can it pay its bills and debts?

Debt to equityBorrowings for every ₹1 of shareholders' money
0.26×
✓ Low debt
Current ratioShort-term assets for every ₹1 due within a year
0.99×
! Tight
Quick ratioLike the current ratio, without inventory
0.64×
! Tight
Interest coverOperating profit ÷ interest to pay
−0.09×
! Weak

Per share What each share stands for

EPS (TTM)
−₹4.25
Book value
₹508.84
Cash flow
₹20.42
Dividend
₹0.00
Revenue
₹134.43

The share price is 3.14× the book value behind each share.

Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.

All 74 metrics from the data provider

Valuation

Current Dividend Yield - Common Stock Primary Issue, LTM0.00
Price to Book - most recent fiscal year3.13
Price to Tangible Book - most fiscal year34.87
Price to sales - most recent fiscal year12.86
Price to Cash Flow per share - trailing 12 month78.01
Price to sales - trailing 12 month11.85
Net Debt, LFY14,564.23

Per share

Cash Flow per share - trailing 12 month20.42
Cash Flow per share - most recent fiscal year17.92
EPS including extraordinary items - trailing 12 month−4.25
EPS including extraordinary items - most recent fiscal year−6.44
EBITD per share - trailing 12 month29.53
Revenue/share - trailing 12 month134.43
EPS excluding extraordinary items - trailing 12 month−4.25
EPS Basic excluding extraordinary items - most recent fiscal year−6.44
EPS Basic excluding extraordinary items - trailing 12 month−4.24
Book value per share - most recent fiscal year508.74
Revenue/share - most recent fiscal year124.12
EPS Normalized - most recent fiscal year−5.87
Book value (tangible) per share - most recent fiscal year45.75
Dividends per share - trailing 12 month0.00
EPS excluding extraordinary items - most recent fiscal year−6.44
Cash per share - most recent fiscal year4.15

Margins

Operating margin - trailing 12 month2.90
Operating margin - 1st historical fiscal year−1.13
Net Profit Margin % - 1st historical fiscal year−5.19
Gross Margin - 1st historical fiscal year66.22
Net Profit Margin % - trailing 12 month−3.15
Pretax margin - 1st historical fiscal year−6.47
Pretax margin - trailing 12 month−4.36
Gross Margin - trailing 12 month67.83

Growth

EPS Change %, TTM over TTM−173.87
Revenue Change % - most recent quarter 1 year ago37.20
Revenue Change %, TTM over TTM4.29
Growth rate% - Revenue, 3 year232.38
EPS Change % - most recent quarter 1 year ago11,000.00

Financial strength

Net Interest coverage - most recent fiscal year−0.09
Free Cash Flow - most recent fiscal year−5,605.46
LT debt/equity - most recent fiscal year0.13
Quick ratio - most recent fiscal year0.64
Current ratio - most recent fiscal year0.99
Total debt/total equity - most recent fiscal year0.26
Net Interest coverage - trailing 12 month0.45

Returns & efficiency

Net Income/employee - trailing 12 month−2,90,442.10
Revenue/employee - most recent fiscal year92,13,156.00
Return on investment - most recent fiscal year−1.12
Return on average assets - most recent fiscal year−0.94
Receivables turnover - most recent fiscal year2.52
Inventory turnover - most recent fiscal year1.36
Revenue/employee - trailing 12 month92,19,492.00
Net Income/employee - most recent fiscal year−4,78,308.50
Asset turnover - most recent fiscal year0.18
Return on average equity - most recent fiscal year−1.26

Price & volume

Market Cap18,323.01
52 week Low Date30 Jan 2026
Price - 1 Day % Change−0.13
Relative (S&P500) price percent change - 13 week7.38
Avg trading volume last 10 days0.32
Price - 13 week price percent change2.48
Price - 52 week price percent change−9.03
Avg Trading Volume Last 3 months6.12
Price - 5 Day % Change0.92
Price % Change Month To Date4.97
Relative (S&P500) price percent change - 04 week9.87
52 week High Date3 Nov 2025
Price - 26 week price percent change19.53
PDATE24 Sep 2026
Price - YTD price percent change−11.93
Relative (S&P500) price percent change - 52 week1.03
NPRICE1,594.60
Relative (S&P500) price percent change - 26 week22.28
52 week Low1,057.00
52 week High1,925.00
Relative (S&P500) price percent change - Year to Date2.00

Dividends & Corporate Events

Payouts to shareholders, splits and bonus issues, and company meetings — newest first.

  • Dividend yield0.00%

No dividends on record.

Corporate calendar

  • MeetingAnnual General Meeting
  • BoardQuarterly Results
  • BoardAudited Results
  • BoardQuarterly Results
  • BoardQuarterly Results
  • MeetingAnnual General Meeting
  • BoardQuarterly Results
  • MeetingPostal Ballot
Show 3 older events
  • MeetingPostal Ballot
  • BoardAudited Results
  • BoardQuarterly Results

About Onesource Specialty Pharma

Biotechnology & Drugs

OneSource Specialty Pharma Limited is an India-based vertically integrated biopharma service company with the capabilities to develop and manufacture complex biologics, biosimilars and vaccines. It operates as a specialty pharma pure-play contract development and manufacturing organization (CDMO). The Company specializes in prefilled syringes (with or without a safety device), dial and push variable and fixed dose pen injectors, pull push fixed dose pens and autoinjectors. Its integrated services offer comprehensive biologics solutions. It supports the development of complex biologics, including microbial and mammalian cell line biopharmaceuticals, cell and gene therapy and ribonucleic acid (RNA) products. The Company caters to a variety of capsule shapes and sizes, as well as formulations, traditional softgels to enteric coated capsules, vegan alternatives, chewable formats, vaginal pessaries, liposomal capsules, applicaps, and suppositories.

Key people

  • Anurag BhaganiaChief Financial Officer
  • Trisha AlladaCompany Secretary, Compliance Officer
  • Neeraj SharmaManaging Director, Executive Director

Company facts

  • NSE symbolONESOURCE
  • BSE code544292
  • ISININE013P01021
  • IndustryBiotechnology & Drugs
  • IndexNIFTY 500
  • Market cap₹18,323 Cr
  • Revenue (FY26)₹1,422 Cr
  • Net profit (FY26)−₹74 Cr

Stock data comes from the exchange feed via our data provider. It is not real-time and can be delayed, so check the price with your broker before you trade. This page is for information and education only. It is not investment advice, research or a recommendation to buy, sell or hold any security. Investments in the securities market are subject to market risks; read all related documents carefully before investing. See all stocks →

Frequently Asked Questions

Onesource Specialty Pharma (NSE: ONESOURCE) last traded at ₹1,600.00 on the NSE, up 0.67% (₹10.65) on the day, as of 25 Sep 2026, 9:59 AM IST. On the BSE it was ₹1,597.85. The day's range was ₹1,567.30 – ₹1,633.55.

Onesource Specialty Pharma's 52-week high is ₹1,924.00 (3 Nov 2025) and its 52-week low is ₹1,075.00 (30 Jan 2026). At ₹1,600.00 the share is 16.8% below its high and 48.8% above its low.

Onesource Specialty Pharma's market capitalisation is ₹18,323 Cr (₹18,323 Cr). It is part of the NIFTY 500 index.

Onesource Specialty Pharma made a loss over the last 12 months, so its P/E ratio is not meaningful. Its earnings per share (TTM) are −₹4.25.

Onesource Specialty Pharma shares are down 9.03% over the last year, down 11.93% so far this year, up 19.53% over 6 months, up 2.48% over 3 months. Over the last year the stock did 1.03% better than the market.

In FY26 (year to Mar 2026), Onesource Specialty Pharma reported revenue of ₹1,422 Cr (down 1.61% on the year before) and a net loss of ₹74 Cr. Earnings per share were −₹6.44.

There is no dividend on record for Onesource Specialty Pharma in the data shown on this page.

As of Jun 2026: Promoter 30.48%, FII 19.19%, MF 12.98%, Other 37.35%.

Onesource Specialty Pharma's listed peers in Biotechnology & Drugs include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Cipla, Zydus Lifesciences. By market capitalisation it ranks #6 of 6 in this group.

No. Onesource Specialty Pharma has debt — its debt-to-equity ratio is 0.26 and total debt was ₹1,504 Cr in FY26. Its operating profit covers interest −0.09 times.